Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.41 |
| ▸ | NAMPT | P43490 | 7/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31234399 | 0.81 | PIK3CD (0.42) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234430 | 0.77 | NAMPT (0.44) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234352 | 0.74 | NAMPT (0.43) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234341 | 0.69 | BTK (0.42) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234220 | 0.68 | ACACB (0.44) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234741 | 0.68 | NAMPT (0.44) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234493 | 0.67 | NAMPT (0.50) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL31234281 | 0.67 | PIK3CD (0.46) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL17456006 | 0.64 | NAMPT (0.46) | PIK3CDPIK3CANAMPTPIK3CBPIK3CG | |
| SCHEMBL12521650 | 0.64 | NPC1 (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | PIK3CD 121/4885PIK3CA 40/4885NAMPT 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.